switching between glp 1 agonists from tirzepatide to retatrutide: the complete transition guide GLP-1-based therapies for type 2
Description
Purpose of Review The development of long-acting incretin receptor agonists represents a significant advance in the fight against the concurrent epidemics of type 2 diabetes mellitus (T2DM) and obesity
Comprehensive Metabolic Health & Fat Metabolism Support
Does retatrutide increase heart rate
The dual GIP/GLP-1 receptor agonist tirzepatide is among the furthest developed multi-agonists for diabetes care and has so far displayed promising nephroprotective effects
Both human and animal studies reported inconsistent BP response to acute administration but showed hypotensive effect of chronic administration of GLP-1/ GLP-1 RAs
Semaglutide was removed in February 2025
